← Back to Screener
enGene Therapeutics Inc. Common Stock (ENGN)
Price$8.08
Favorite Metrics
Price vs S&P 500 (26W)0.74%
Price vs S&P 500 (4W)2.26%
Market Capitalization$519.84M
All Metrics
Book Value / Share (Quarterly)$4.20
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.55
Price vs S&P 500 (YTD)-16.71%
EPS (TTM)$-2.25
10-Day Avg Trading Volume0.20M
EPS Excl Extra (TTM)$-2.25
EPS (Annual)$-2.29
ROI (Annual)-61.40%
Cash / Share (Quarterly)$4.12
ROA (Last FY)-52.97%
EBITD / Share (TTM)$-2.33
ROE (5Y Avg)-45.63%
Cash Flow / Share (Annual)$-1.94
P/B Ratio1.85x
P/B Ratio (Quarterly)2.38x
Net Income / Employee (Annual)$-3
Net Interest Coverage (TTM)-2.94x
ROA (TTM)-45.74%
EPS Incl Extra (Annual)$-2.29
Current Ratio (Annual)6.30x
Quick Ratio (Quarterly)11.26x
3-Month Avg Trading Volume0.37M
52-Week Price Return94.00%
Revenue / Employee (TTM)$0
52-Week High$12.25
EPS Excl Extra (Annual)$-2.29
26-Week Price Return4.72%
Quick Ratio (Annual)6.09x
13-Week Price Return-6.51%
Total Debt / Equity (Annual)0.14x
Current Ratio (Quarterly)11.75x
Enterprise Value$508.149
Revenue / Employee (Annual)$0
Cash / Share (Annual)$3.72
3-Month Return Std Dev84.57%
Net Income / Employee (TTM)$-3
ROE (Last FY)-69.94%
EPS Basic Excl Extra (Annual)$-2.29
Total Debt / Equity (Quarterly)0.09x
EPS Incl Extra (TTM)$-2.25
ROI (TTM)-50.38%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)64.17%
Year-to-Date Return-14.06%
5-Day Price Return6.74%
EPS Normalized (Annual)$-2.29
ROA (5Y Avg)-57.58%
Month-to-Date Return13.95%
EBITD / Share (Annual)$-2.41
LT Debt / Equity (Annual)0.09x
ROI (5Y Avg)-40.33%
LT Debt / Equity (Quarterly)0.09x
EPS Basic Excl Extra (TTM)$-2.25
P/B Ratio (Annual)2.20x
Book Value / Share (Annual)$3.22
Price vs S&P 500 (13W)-7.19%
Beta-0.00x
Revenue / Share (TTM)$0.00
ROE (TTM)-55.83%
52-Week Low$2.65
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.29
4.33
4.33
4.33
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ENGNenGene Therapeutics Inc. Common Stock | — | — | — | — | $8.08 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
enGene Holdings is a clinical-stage biotech company developing localized gene therapies using its proprietary non-viral DDX delivery platform. The company is initially targeting non-muscle invasive bladder cancer (NMIBC) and aims to expand to other high-need diseases through direct delivery to mucosal tissues and organs.